共 50 条
Molecular profiling of clear cell adenocarcinoma of the urinary tract
被引:17
|作者:
Lin, Chieh-Yu
[1
,2
]
Saleem, Atif
[2
]
Stehr, Henning
[2
]
Zehnder, James L.
[2
]
Pinsky, Benjamin A.
[2
,3
]
Kunder, Christian A.
[2
]
机构:
[1] Washington Univ, Dept Pathol & Immunol, Sch Med, Campus Box 8118,660 South Euclid Ave, St Louis, MO 63110 USA
[2] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Sch Med, Stanford, CA 94305 USA
关键词:
Clear cell adenocarcinoma;
Urinary tract;
Molecular profiling;
PIK3CA;
KRAS;
UROTHELIAL CARCINOMA;
NEPHROGENIC ADENOMA;
BLADDER;
PIK3CA;
HISTOGENESIS;
MUTATIONS;
TUMORS;
D O I:
10.1007/s00428-019-02634-5
中图分类号:
R36 [病理学];
学科分类号:
100104 ;
摘要:
Clear cell adenocarcinoma (CCA) of the urinary tract is a rare type of malignancy whose molecular profiles remain undefined. Here we reported an integrated clinicopathologic and molecular profiling analysis of four cases of clear cell adenocarcinoma arising in the urethra or the bladder. Utilizing a clinically validated 130-gene exon-sequencing assay, we identified recurrent pathogenic PIK3CA (p. E545K) and KRAS (p.G12D) variants in three of four (75%) of the cases. In addition, an APC variant (P.S2310X), a TP53 variant (p.R273C), and a MYC amplification event were identified. The only CCA case without either PIK3CA or KRAS variants has a distinct pathogenesis through BK virus, demonstrated by positive BK virus PCR and SV40 immunohistochemistry. The novel finding of recurrent variants in the PI3K/AKT/mTOR pathway provides not only insights into oncogenesis but also potential clinical therapeutic targets for patients with clear cell adenocarcinoma of the urinary tract.
引用
收藏
页码:727 / 734
页数:8
相关论文